Nuzyra
nuzyra.com
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Visit the official Patient site to find out why NUZYRA® might be right for you. See Important Safety Information and Full Prescribing Information.
News
Paratek Pharmaceuticals Announces Positive Results for NUZYRA Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary AnthraxOral NUZYRA Tablets Produced in the U.S. as a Result of the Company
Read more
Report
Paratek Pharmaceuticals To Present New Data On NUZYRA (Omadacycline) At Idweek 2025 And CHEST 2025
Read more
Report
Paratek Pharmaceuticals to Present New Data on NUZYRA (omadacycline) at ESCMID Global 2025
Highlights will include data from non-clinical and real-world patient useBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health
Read more
Report
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
media466326
Read more
Report
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study Of NUZYRA (Omadacycline) Demonstrating No Change In In Vitro Potency Against Indicated Pathogens
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study Of NUZYRA (Omadacycline) Demonstrating No Change In In Vitro Potency Against Indicated Pathogens. - No Emergence of Resistance was Observed- Additional Years of Surveillance are
Read more
Report
Report
Paratek Pharmaceuticals Presenting New Data for NUZYRA (omadacycline) at IDWeek 2021
Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infectionsBOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Parat
Read more
Report
Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
--Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the company has withdrawn its submission to the European Medicines Agency of th
Read more
Report